Clinical Trials for Mesothelioma Patients—Electronic Tool to Record Cancer Symptoms: Study Outcomes Measures

Read about the primary and secondary electronic outcomes measures for a current clinical trial being conducted on patients with advanced cancer or malignant mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This trial is currently only being conducted in Switzerland.

Primary Outcome Measures:

Change in global quality of life (G-QOL) as measured at baseline and after study completion

Secondary Outcome Measures:

• G-QOL after study completion
• Communication as measured by patients' estimation of physicians' compassion and attribute and physicians' satisfaction with patient-physician communication
• Change in symptoms and syndromes as measured by difference in Edmonton Symptom Assessment Scale Score, Karnofsky performance status, weight, shortness of breath, nutritional intake, and 3 patient chosen symptoms at baseline and after study completion
• Symptom management performance as measured by number of visits with a symptom load above a defined threshold of 5 symptoms without immediate intervention and number of accompanying persons in weeks 3-6
• Factors influencing the change in G-QOL (i.e., tumor response [complete and partial response, stable or progressive disease], tumor type, predominant symptom, anxiety, complexity, education, hospitalization)
• Change in burden of illness and treatment over time
• Comparison of the number of mismatched decision-making preferences between weeks 3-6

Recruitment Information:

Status: Recruiting

Enrollment: 1992

Start Date: February 2007

Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)